

Amendments to the Claims:

1. (currently amended) A pharmaceutical composition comprising:
 - (a) solubilized (2S,3S,5S)-5-(N-(N-methyl-N-((2-isopropyl-4-thiazolyl)-methyl)amino)carbonyl)-L-valinyl)amino-2-(N-((5-thiazolyl)methoxy-carbonyl)-amino)-1,6-diphenyl-3-hydroxyhexane (ritonavir) or a combination of solubilized (2S,3S,5S)-5-(N-((N-methyl-N-((2-isopropyl-4-thiazolyl)-methyl)amino)carbonyl)-L-valinyl)amino-2-(N-((5-thiazolyl)methoxy-carbonyl)-amino)-1,6-diphenyl-3-hydroxyhexane (ritonavir) and another HIV protease inhibiting compound, or pharmaceutically acceptable salts thereof, in an amount of from ~~about~~ 1 to ~~about~~ 50 weight % of the composition;
 - (b) a pharmaceutically acceptable organic solvent which comprises a medium and/or long chain fatty acid or a mixture thereof in an amount of from ~~about~~ 40 to ~~about~~ 75 weight % of the composition, and ethanol or propylene glycol in an amount of from ~~about~~ 1 to ~~about~~ 15 weight % of the composition;
 - (c) water in an amount of from ~~about~~ 0.4 to ~~about~~ 3.5 weight % of the composition; and
 - (d) optionally, a pharmaceutically acceptable surfactant[.];

wherein the total of (a), (b), (c), and if present (d), is 100% of the pharmaceutical composition.

2. (canceled)
3. (previously presented) The composition according to claim 1 comprising a combination of ritonavir and (2S, 3S, 5S) -2- (2,6-dimethylphenoxyacetyl)-amino-3-hydroxy-5-(2S-(1-tetrahydropyrimid-2-only)-3-methyl-butanoyl)amino-1,6-diphenylhexane.
4. (previously presented) The composition according to Claim 1 comprising ritonavir or a combination of ritonavir and another HIV protease inhibiting compound selected from the group consisting of: (2S,3S,5S)-2-(2,6-dimethylphenoxyacetyl)-amino-3-hydroxy-5-(2S-(1-tetrahydropyrimid-2-onyl)-3-methyl-butanoyl)amino-1,6-diphenylhexane;

N-(2(R)-hydroxy-1(S)-indanyl)-2(R)-phenylmethyl-4(S)-hydroxy-5-(1-(4-(3-pyridylmethyl)-2(S)-N'-(t-butylcarboxamido)-piperazinyl))-pentaneamide (indinavir);


N-tert-butyl-decahydro-2-[2(R)-hydroxy-4-phenyl-3(S)-[[N-(2-quinolylcarbonyl)-L-asparaginyl]amino]butyl]-4aS,8aS)-isoquinoline-3(S)-carboxamide (saquinavir);


5(S)-Boc-amino-4(S)-hydroxy-6-phenyl-2(R)-phenylmethylhexanoyl-(L)-Val-(L)-Phe-morpholin-4-ylamide;

1 -Naphthoxyacetyl-beta-methylthio-Ala-(2S, 3S)- 3-amino-2-hydroxy-4-butanoyl 1,3-thiazolidine-4-t-butylamide;


5-isoquinolinoxyacetyl-beta-methylthio-Ala-(2S,3S)-3-amino-2-hydroxy-4-butanoyl-1,3-thiazolidine-4-t-butylamide;

[1S-[1R-(R-),2S*])-N¹ [3-[[[(1,1 -dimethylethyl)amino]carbonyl](2-methylpropyl)amino]-2-hydroxy-1 -(phenylmethyl)propyl]-2-[(2quinolinylcarbonyl)amino]-butanediamide;








;




;




;



;



; and



[tipranavir] ;

or a pharmaceutically acceptable salt thereof.

5. (previously presented) The composition according to claim 1 wherein said fatty acid is oleic acid.

6. (previously presented) The composition according to claim 1 wherein said surfactant is Polyoxy 35 castor oil.
7. (currently amended) The composition according to claim 1 wherein the pharmaceutical composition solution is encapsulated into a hard gelatin capsule or a soft gelatin capsule.
8. (currently amended) The composition of Claim 1 wherein the pharmaceutically acceptable organic solvent comprises (1) a pharmaceutically acceptable long chain fatty acid in an amount of from ~~about~~ 40 to ~~about~~ 75 weight % of the composition; and (2) ethanol or propylene glycol in an amount of from ~~about~~ 3 to ~~about~~ 12 weight % of the composition; ~~and (3) water in an amount of from about 0.4 to about 1.5 weight % of the composition.~~
9. (currently amended) The composition of Claim 1 wherein the pharmaceutically acceptable organic solvent comprises (1) oleic acid in an amount of from ~~about~~ 40 to ~~about~~ 75 weight % of the composition; (2) ethanol or propylene glycol in an amount of from ~~about~~ 3 to ~~about~~ 12 weight % of the composition; ~~and (3) water in an amount of from about 0.4 to about 1.5 weight % of the composition.~~
10. (previously presented) The composition of Claim 9 comprising ritonavir or a combination of ritonavir and another HIV protease inhibiting compound selected from the group consisting of:

(2S, 3S, 5S)-2-(2,6Dimethylphenoxyacetyl)amino-3-hydroxy-5-[2S-(1-tetrahydro-pyrimid-2-onyl)-3-methyl butanoyl]-amino-1,6-diphenylhexane;

N-(2(R)-hydroxy-1(S)-indanyl)-2(R)-phenylmethyl-4(S)-hydroxy-5-(1-(4-(3-pyridylmethyl)-2(S)-N'-(t-butylcarboxamido)-piperazinyl))-pentaneamide (indinavir);



N-tert-butyl-decahydro-2-[2(R)-hydroxy-4-phenyl-3(S)-[[N-(2-quinolylcarbonyl)-L-asparaginyl]amino]butyl]-(4aS,8aS)-isoquinoline-3(S)-carboxamide (saquinavir);





5(S)-Boc-amino-4(S)-hydroxy-6-phenyl-2(R)-
phenylmethylhexanoyl-(L)-Val-(L)-Phe-morpholin-4-ylamide;


1 -Naphthoxyacetyl-beta-methylthio-Ala-(2S, 3S)- 3-amino-2-hydroxy-4-butanoyl
1,3-thiazolidine-4-t-butylamide;

5-isoquinolinoxyacetyl-beta-methylthio-Ala-(2S,3S)-3-amino-2-hydroxy-4-butanoyl-1,3-thiazolidine-4-t-b
utylamide;


[1S-[1R-(R-),2S*]]-N^I [3-[[[(1,1 -dimethylethyl)amino]carbonyl](2-methylpropyl)amino]-2-
hydroxy-1 -(phenylmethyl)propyl]-2-[(2-quinolinylcarbonyl)amino]-butanediamide;







; and



[tipranavir];



or a pharmaceutically acceptable salt thereof.

11. (previously presented) The composition of Claim 9 comprising (2S,3S,5S)-5-(N-(N-((N-methyl-N-((2-isopropyl-4-thiazolyl)-methyl)amino)carbonyl)-L-valinyl)amino-2-(N-((5-thiazolyl)methoxy-carbonyl)-amino)-1,6-diphenyl-3-hydroxyhexane (ritonavir) or a combination of (2S,3S,5S)-5-(N-(N-((N-methyl-N-((2-isopropyl-4-thiazolyl)-methyl)amino)carbonyl)-L-valinyl)amino-2-(N-((5-thiazolyl)methoxy-carbonyl)-amino)-1,6-diphenyl-3-hydroxyhexane (ritonavir) and another HIV protease inhibiting compound selected from the group consisting of:


(2S, 3S, 5S)-2-(2,6-dimethylphenoxyacetyl) amino-3-hydroxy-5-(2S-(1-tetrahydro-pyrimid-2-onyl)-3-methylbutanoyl)- amino-1,6-diphenylhexane,

N-(2(R)-hydroxy-1(S)-indanyl)-2(R)-phenylmethyl-4(S)-hydroxy-5-(1-(4-(3-pyridylmethyl)-2(S)-N'-(t-butylcarboxamido)-piperazinyl))-pentaneamide (indinavir),

N-tert-butyl-decahydro-2-[2(R)-hydroxy-4-phenyl-3(S)-[[N-(2-quinolylcarbonyl)-L-asparaginyl]amino]butyl]- (4aS,8aS)-isoquinoline-3(S)-carboxamide (saquinavir),



and



or a pharmaceutically acceptable salt thereof.

12. (original) The composition of claim 1 wherein the HIV protease inhibiting compound is ritonavir or a combination of ritonavir and another protease inhibiting compound.
13. (original) The composition of claim 12 wherein the solution is encapsulated in a soft elastic gelatin capsule (SEC).
14. (currently amended) The composition of Claim 1 which comprises:
 - (a) solubilized (2S,3S,5S)-5-(N-(N-((N-methyl-N-((2-isopropyl-4-thiazolyl)-methyl)amino)carbonyl)-L-valinyl)amino-2-(N-((5-thiazolyl)methoxy-carbonyl)-amino)-1,6-diphenyl-3-hydroxyhexane (ritonavir) in an amount of from **about** 1 to **about** 30 weight % of the composition;
 - (b) a pharmaceutically acceptable organic solvent which comprises (1) oleic acid in an amount of from **about** 30 to **about** 75 weight % of the composition and (2) ethanol in an amount of from **about** 3 to **about** 12 weight % of the composition; and
 - (c) water in an amount of from **about** 0.4 to **about** 3.5 weight % of the composition; and
 - (d) polyoxyl 35 castor oil in an amount of from **about** 0 to **about** 20 weight % of the composition.
15. (currently amended) A pharmaceutical composition comprising:
 - (a) (2S,3S,5S)-5-(N-(N-((N-methyl-N-((2-isopropyl-4-thiazolyl)-methyl)amino)carbonyl)-L-valinyl)amino-2-(N-((5-thiazolyl)methoxy-carbonyl)-amino)-1,6-diphenyl-3-hydroxyhexane (ritonavir) in an amount of **about** 10 weight % of the composition;
 - (b) a pharmaceutically acceptable organic solvent which comprises (1) oleic acid in an amount of from **about** 70 to **about** 75 weight % of the composition; and (2) ethanol in an amount of from **about** 3 to **about** 12 weight % of the composition;
 - (c) water in an amount of from **about** 0.4 to **about** 1.5 weight % of the composition; and
 - (d) polyoxyl 35 castor oil in an amount of **about** 6 weight % of the composition.

16. (currently amended) The composition of claim 15 wherein the **pharmaceutical composition solution** is encapsulated in a soft elastic gelatin capsule (SEC).

17. (currently amended) The composition of Claim 1 which comprises:

(a) a combination of (2S,3S,5S)-5-(N-(N-methyl-N-((2-isopropyl-4-thiazolyl)-methyl)amino)carbonyl)-L-valinyl)amino-2-(N-((5-thiazolyl)methoxy-carbonyl)-amino)-1,6-diphenyl-3-hydroxyhexane (ritonavir) and (2S, 3S, 5S)-2-(2,6-dimethylphenoxyacetyl) amino-3hydroxy-5-(2S-(1-tetrahydro-pyrimid-2-onyl)-3-methyl butanoyl)- amino-1,6--diphenylhexane in an amount of from **about** 1 to **about** 45 weight % of the composition;

(b) a pharmaceutically acceptable organic solvent which comprises (1) oleic acid in an amount of from **about** 30 to **about** 75 weight % of the composition and (2) propylene glycol in an amount of from **about** 1 to **about** 15 weight % of the composition; and

(c) water in an amount of from **about** 0.4 to **about** 3.5 weight % of the composition.

18. (currently amended) The composition of Claim 17 which comprises:

(a) a combination of (2S,3S,5S)-5-(N-(N-methyl-N-((2-isopropyl-4-thiazolyl)-methyl)amino)carbonyl)-L-valinyl)amino-2-(N-((5-thiazolyl)methoxy-carbonyl)-amino)-1,6-diphenyl-3-hydroxyhexane (ritonavir) and (2S, 3S, 5S)-2-(2,6-dimethylphenoxyacetyl) amino-3hydroxy-5-(2S-(1-tetrahydro-pyrimid-2-onyl)-3-methyl butanoyl) amino-1,6--diphenylhexane in an amount of from **about** 1 to **about** 45 weight % of the composition;

(b) a pharmaceutically acceptable organic solvent which comprises (1) oleic acid in an amount of from **about** 70 to **about** 75 weight % of the composition; and (2) propylene glycol in an amount of from **about** 1 **about** 8 weight % of the composition;

(c) water in an amount of from **about** 0.4 to **about** 1.5 weight % of the composition; and

(d) polyoxyl 35 castor oil in an amount of from **about** 2.5 to **about** 10 weight % of the composition.

19. (currently amended) The composition of claim 18 wherein the **composition-solution** is encapsulated in a soft elastic gelatin capsule (SEC).

20. (currently amended) A pharmaceutical composition comprising:

- (a) a combination of solubilized (2S,3S,5S)-5-(N-(N-methyl-N-((2-isopropyl-4-thiazolyl)-methyl)amino)carbonyl)-L-valinyl)amino-2-(N-((5-thiazolyl)methoxy-carbonyl)-amino)-1,6-diphenyl-3-hydroxyhexane (ritonavir) in an [the] amount of about 3.9 weight % of the composition [by weight of the total solution] and (2S, 3S, 5S)-2-(2,6-dimethylphenoxyacetyl) amino-3hydroxy-5-(2S-(1-tetrahydro-pyrimid-2-onyl)-3-methyl butanoyl) amino-1,6-diphenylhexane in an amount of **about** 15.6 weight % of the composition;
- (b) a pharmaceutically acceptable organic solvent which comprises (1) oleic acid in an amount of **about** 70 weight % of the composition; and (2) propylene glycol in an amount of **about** 7.5 weight % of the composition;
- (c) water in an amount of **about** 0.5 weight % of the composition; and
- (d) polyoxyl 35 castor oil in an amount of **about** 2.5 weight % of the composition.

21. (currently amended) The composition of claim 20 wherein the pharmaceutical composition solution is encapsulated in a soft elastic gelatin capsule (SEC).